Abstracts tagged "socio-economic inequities"

Abstract Number: 217 • 2018 ACR/ARHP Annual Meeting
Association between Comorbidities and Socioeconomic Status Among Patients with Rheumatoid Arthritis in Korea
Seunghwan Shin¹, Anna Shin¹, Ji Hyoun Kim², You-Jung Ha¹, Yun Jong Lee¹, Yeong Wook Song³ and Eun Ha Kang¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of (South), ²Department of Internal Medicine, Chungbuk National University Hospital, Chungcheongbuk-do, Korea, Republic of (South), ³Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Increased prevalence of comorbidities in patients with rheumatoid arthritis (RA) compared to general population has been noted in several previous study. This study aims…
Abstract Number: 119 • 2016 ACR/ARHP Annual Meeting
Impact of Socioeconomic Status on Disease Outcomes in Japanese Patients with Rheumatoid Arthritis Under the Japanese National Insurance System
Akira Onishi¹, Goichi Kageyama², Yo Ueda², Ikuko Naka², Kosaku Tsuda², Takaichi Okano², Soshi Takahashi², Kengo Akashi², Sho Sendo², Yoshinori Kogata², Jun Saegusa² and Akio Morinobu², ¹Department for Rheumatology, Kobe University Hospital, Kobe, Japan, ²Department of Rheumatology, Kobe University Hospital, Kobe, Japan
Background/Purpose: Several studies showed lower socioeconomic status (SES) was associated with higher disease activity and lower quality of life (QOL) in patients with rheumatoid arthritis…
Abstract Number: 2118 • 2014 ACR/ARHP Annual Meeting
Lower Socioeconomic Status at Disease Onset Is Associated with Higher Health Care Costs in Patients with Systemic Lupus Erythematosus: A General Population-Based Cohort Study
Natalie McCormick¹, Mohsen Sadatsafavi², Wenjia Chen³, Carlo A. Marra⁴ and J. Antonio Avina-Zubieta⁵, ¹Faculty of Pharmaceutical Sciences, University of British Columbia/Arthritis Research Centre of Canada, Vancouver, BC, Canada, ²Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada, ³Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, ⁴Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: Low socioeconomic status (SES) negatively impacts health outcomes in the general population, as well as in systemic lupus erythematosus (SLE), but the impact on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].